BACKGROUND/OBJECTIVES: Vitamin D deficiency has been associated with impaired resistance to infection, which may be mediated by alterations in cytokine responses. We investigated the effect of vitamin D supplementation to infants on whole blood in-vitro cytokine production and on the inflammatory marker, plasma C-reactive protein (CRP). SUBJECTS/METHODS: Blood samples were taken at 6 months of age from infants participating in the DIVIDS (Delhi Infant Vitamin D Supplementation) randomized controlled trial of weekly vitamin D supplements (1400 IU ¼ recommended intake) from birth to 6 months with the aim of decreasing mortality and severe morbidity. We measured plasma CRP and whole blood in-vitro production of tumour necrosis factor-a (TNFa), interferon-g (INFg), interleukin (IL)-10 and IL-13 following no stimulation or stimulation with lipopolysaccharide or phytohemagglutinin. RESULTS: Although the intervention improved vitamin D status in a severely deficient population, there were no differences between treatment groups in plasma CRP or in the production of any of the cytokines in either unstimulated or stimulated cultures. Recent illness had limited association with immunological markers. Plasma 25-hydroxyvitamin D levels were not associated with CRP or production of any cytokines. CONCLUSIONS: Vitamin D supplementation did not affect plasma CRP or whole blood cytokine production of vitamin Ddeficient low birth weight infants. This is consistent with the lack of effect of vitamin D on mortality and severe morbidity among infants in the DIVIDS trial.
INTRODUCTION
Cross-sectional and longitudinal studies have shown associations between low vitamin D status, as indicated by plasma 25-hydroxyvitamin D (25OHD), and increased morbidity or mortality, especially from respiratory diseases. 1 --4 Interpretation of such observational results is difficult for many reasons including that some authors, 5 although not all, 6, 7 have suggested that 25OHD is a negative acute phase reactant and thus not a valid measure of vitamin D status in people with infections or inflammation. A recent meta-analysis evaluating association of 25OHD and mortality in observational studies suggests a reduction in mortality risk with increases in circulating in 25OHD levels. 8 There is increasing laboratory and experimental animal evidence for a role of vitamin D in innate immunity, inflammation and immunoregulation. Treatment of dendritic cells with 1,25-dihyroxyvitamin D (1,25(OH)2D), the active metabolite of vitamin D, prevented their maturation in response to lipopolysaccharide (LPS) stimulation. 9 This lack of dendritic cell maturation was associated with enhanced interleukin (IL)-10 secretion and impaired activation of T cells to produce interferon-g (IFNg). 9, 10 In-vivo treatment of mice with 1,25(OH)2D decreased tumour necrosis factor-a (TNFa) production. 11 There are some data on cytokine responses to vitamin D supplementation of humans. In a randomized controlled trial involving 93 middle-aged patients with congestive heart failure, 9 months of a high daily dose, 50 mg, of vitamin D3 decreased plasma TNFa and increased IL-10 compared with controls. 12 Similarly, daily supplementation of 83.3 mg of vitamin D3 to 200 healthy overweight subjects for 12 months resulted in significant decrease in serum TNFa concentration even after adjustment for fat mass and waist circumference. 13 In a small trial involving 39 patients with multiple sclerosis, 6 months of 25 mg vitamin D daily had no effect on blood mononuclear cell mRNA for the inflammatory cytokines, IFNg and TNFa, or the anti-inflammatory cytokine, IL-13.
14 It is possible that low dose, rather than low sample size, was the reason for lack of effect since a trial with 24 healthy but vitamin D-deficient adults found that large doses of vitamin D given as depot injections decreased the inflammatory marker, C-reactive protein (CRP) after a year. 15 However, a trial with both large sample size, 324 overweight people, and high vitamin D dose, either 500 or 1000 mg per week for a year, found no consistent effects on CRP or a large array of plasma cytokines including IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-17 and IFNg. 16 It is likely that the very different populations examined in these trials could explain the variant results so it is important to study additional populations and to include both clinical and immunological outcomes together.
We investigated potential cytokine mechanisms within the context of a large randomized controlled trial of vitamin D supplements to low birth weight Indian neonates. We selected both pro-and anti-inflammatory cytokines for investigation: IL-10, IL-13, IFNg and TNFa. Whole blood cytokine production was measured, rather than production in isolated enumerated leukocytes, because it represents a person's overall production and is technically easier with limited laboratory facilities.
MATERIALS AND METHODS

Design and intervention
We conducted an individually randomized, double blind, placebo controlled trial of weekly vitamin D supplementation of Indian infants for the first 6 months of life: the Delhi Infant Vitamin D Supplementation (DIVIDS) study, the detailed methods for which are published elsewhere. 17 In brief, 2079 low birth weight (1.8 to o2.5 kg) term (437 weeks gestation) infants born at Safdarjung Hospital, New Delhi were enrolled on the study within 48 h of birth. At enrolment, the infants were randomized to receive each week, starting at 7 days of age and continuing to 6 months, either 35 mg (1400 IU ¼ 1 recommended dietary allowance) granulated vitamin D3 (cholecalciferol) or an identical appearing and tasting placebo. At the completion of 6 months, blood was collected for analysis of plasma 25OHD and CRP and in-vitro whole blood production of the cytokines IL-10, IL-13, TNFa and IFNg.
Blood collection
For logistical reasons, blood collection began partway through the trial. Blood (4 ml) was collected from infants by venipuncture into lithium heparinized vacutainers. Vacutainers were transferred from Safdarjung Hospital to the laboratory in an ice box. Of the 459 blood samples collected, only 358 samples from these small infants provided sufficient volume for whole blood cytokine production.
Whole blood cytokine production
In the laboratory, 200 ml of fresh blood was aliquoted into sterile tubes containing 800 ml RPMI medium (RPMI 1640, Cat No. 2240089, Gibco (Life Technologies, Grand Island, NY, USA), Invitrogen (Laboratory Services, Carlsbad, CA, USA), supplemented with L-glutamine and 25 mM HEPES). Penicillin and streptomycin were added into the medium to inhibit bacterial growth. Phytohemagglutinin (PHA; from Phaseolus vulgaris, No. L1668; Sigma, Poole, UK) in doses of 1 and 5 mg/ml or LPS (from Escherichia coli, No. L2654; Sigma) in doses of 1 mg/ml and 10 ng/ml were used for stimulation of whole blood cytokine production. Vials containing only 200 ml blood and 800 ml RPMI were also prepared for control, unstimulated samples. Tubes were incubated at 37 1C in an incubator for 24 and 72 h and the supernatant fluid was collected and frozen at À80 1C for cytokine analysis.
The supernatants were assessed for cytokine concentration by ELISA (enzyme-linked immunosorbent assay). Initially, ELISAs were run using five to seven arbitrarily selected samples to see which conditions gave the strongest responses; 5 mg PHA and 1mg LPS doses were selected. IL-10, IL-13, TNFa were analysed using 24 h supernatant fluid. IFNg concentrations were higher at 72 h, so 72 h samples were selected for IFNg. In each case, supernatant samples from unstimulated cultures were run on the same plate. Each assay was standardized against an external quality control (National Institute for Biological Standards and Control, UK). Pooled supernatant fluid samples from cultures obtained from laboratory staff were also run with each assay as internal controls. Inter-assay coefficients of variation were all o3% and values for the external quality controls were within expected limits.
Plasma 25OHD and CRP measurement
The blood remaining after removal of 1200 ml for cytokine production was centrifuged and plasma stored at À80 1C for CRP and 25OHD analyses. Plasma 25OHD concentration was determined by radioimmunoassay (Diasorin 25OHD 125 I RIA, Cat No. 68100E, Stillwater, MN, USA), as described previously. 17 Plasma CRP concentrations were measured by sandwich ELISA with the use of antibodies (Mouse Monoclonal (C4) to CRP, Abcam (Cambridge, UK), ab10028, Goat Polyclonal to CRP (Horse Radish Peroxidase), Abcam, ab19175) and control serum from Dako Ltd, Cambridgeshire, UK (code-X0925). N-rheumatology standard serum from Dade Behring (Seimens Healthcare Diagnostics Inc., Tarry town, NY, USA) (cat No. OQKZ13) was used for calibration. Samples were diluted 1:100. All chemicals required for analysis were procured from Amresco Inc. (Solon, OH, USA) ACS grade. An internal control of pooled plasma from laboratory staff was run with each assay. Inter-assay coefficients of variation were 1.1 and 1.3% for external (National Institute for Biological Standards and Control, UK) and internal quality controls, respectively.
Statistics
Data were double entered in Microsoft Access and cross-checked before importing into Stata 11.1 (StataCorp., College Station, TX, USA) for analysis. Cytokine and CRP results were log-transformed to normalize distributions; geometric means and 95% confidence intervals (CIs) are presented. SES (socioeconomic status) quintiles were calculated based on an asset index. 18 Initial analyses for CRP and for basal and stimulated cytokines compared the crude effect of vitamin D versus placebo by t-test. Several potential effect modifiers---infant sex, birth weight, infant morbidity over the past 3 days as reported by the mother, severe morbidity defined as hospitalization since birth, and SES quintile---were analysed for associations with cytokine production. Since cytokines were measured, by plan, only in a subset and since there was a biased loss to follow-up in the full cohort, 17 baseline characteristics were compared between those who did and did not have cytokine results. Analyses adjusting for all characteristics associated with missingness were then carried out, assuming data were missing at random.
In view of the discordant published results as to whether or not plasma 25OHD decreases during acute phase responses, we analysed whether 25OHD differed between children who had or had not experienced morbidity in the past 3 days or hospitalization since birth.
The sample size of 358 was sufficient to detect, at 90% power, group differences of 0.12 times the standard deviation in the immunological outcomes.
RESULTS
Baseline and sociodemographic characteristics of the participants from the cytokine subset and full cohort are shown in Table 1 . There were no differences by treatment group in either the full or subset populations. However, the subset for which cytokine results were available differed from the full cohort for maternal body mass index, family type, family size, maternal education, father's occupation and socioeconomic quintile; overall the cytokine cohort was of slightly higher socioeconomic status than the full cohort. There were no differences between treatment groups in stimulated or unstimulated concentrations of any cytokines measured (Table 2) . Plasma CRP did not differ between treatment groups: geometric mean 0.24 mg/l (95% CI: 0.20, 0.28) in the vitamin D group and 0.20 mg/l (95% CI: 0.17, 0.23) in the placebo group (P ¼ 0.11). Plasma 25OHD was not significantly correlated with CRP or any cytokine measure (results not presented).
Only IFNg levels differed by sex with the 176 boys having higher levels than the 182 girls for unstimulated (93 (95% CI: 79, 110) pg/ml versus 68 (95% CI: 57, 80) pg/ml; P ¼ 0.03), PHA-stimulated (164 (95% CI: 140, 192) pg/ml, versus 126 (95% CI: 107, 149) pg/ml; P ¼ 0.07), and LPS-stimulated (302 (95% CI: 257, 354) pg/ml versus 244 (95% CI: 207, 287) pg/ml; P ¼ 0.007) cultures. SES asset index quintiles were not significantly associated with cytokine production. Neither reported overall health in the past month nor reported symptoms in the past 3 days was associated with plasma CRP or most cytokines but the statistical power was limited since the only symptom reported in 410% of the infants was cough. The exception was that IL-13 was higher in the 22 children with reported skin conditions in the past 3 days compared with the 336 children without skin problems for unstimulated (20 (95% CI: 11, 36) pg/ml versus 9 (95% CI: 8, 11) pg/ml; P ¼ 0.008), PHA-stimulated (28 (95% CI: 17, 45) pg/ml versus 13 (95% CI: 12, 15) pg/ml; P ¼ 0.003), and LPSstimulated (35 (95% CI: 21, 57) pg/ml versus 18 (95% CI: 16, 20) pg/ml; P ¼ 0.005) cultures.
Effects of vitamin D treatment on cytokine production were analysed by linear regression controlling for variables, which differed between the cytokine subset and the full cohort as well as sex for IFNg. The vitamin D treatment effect remained non-significant for all cytokines (results not presented).
Vitamin D supplementation resulted in higher mean plasma 25OHD values at 6 months and a lower proportion of infants deficient in vitamin D (Table 3) . These results from the cytokine subset were similar to those from the full cohort. 17 There was no difference in plasma 25OHD between infants who were or were not hospitalized during the study: 18.6 ng/ml (s.d. 9.9, n ¼ 46) and 18.0 ng/ml (s.d. 10.5, n ¼ 407), respectively; P ¼ 0.71. The only symptom in the past 3 days, which was significantly (P ¼ 0.009) associated with 25OHD, was diarrhoea; 22 infants who had had diarrhoea had 25OHD 13.0 ng/ml (s.d. 6.1) compared with 19.1 ng/ml (s.d. 10.7) in 329 infants without diarrhoea. Significant difference between the cytokine subset and the full cohort: maternal body mass index P ¼ 0.004; family type Po0.001; family size P ¼ 0.04; mothers' education P ¼ 0.004; fathers' occupation Po0.001; asset index P ¼ 0.004.
DISCUSSION
Vitamin D supplementation had no effect on plasma CRP or whole blood in-vitro cytokine production although it improved the vitamin D status and growth in the supplemented infants. 17 The lack of effect on CRP and cytokines supports the primary trial result that vitamin D supplementation had no effect on mortality or hospitalization. There are several possible reasons for the lack of effects on cytokine production in the DIVIDS trial, in contrast to the extensive in vitro and animal model literature, which suggests that effects would be detected. First, as for the clinical results, 17 it is possible that exclusive or predominant breastfeeding of the infants in the DIVIDS study masked any immunological benefits of other nutritional interventions. Second, the amount of vitamin D needed to affect cytokine production and other immune functions may be larger than amounts needed to increase plasma 25OHD and growth. Although supplementation of vitamin D at one recommended dietary allowance in our trial resulted in significant increase in vitamin D status, other studies have reported larger effects with similar doses. 19 It is interesting that a trial which detected changes in plasma TNFa and IL-10 used in adults a daily dose which was 10 times that we used for the DIVIDS infants. 12 However, a large trial with an even larger vitamin D dose found no effects on a large array of cytokines including the ones measured in the present study. 16 It is notable that the sample size of the present study was sufficient to detect small treatment group differences, about 10% of a standard deviation, at high statistical power. Third, we used stimulation in vitro with optimal concentrations of PHA or LPS, which could have overcome modest differences between groups in blood cell populations or their degree of responsiveness; suboptimal concentrations might have revealed such modest differences. An additional methodological difference between our and other vitamin D intervention trials is that while we used whole blood stimulation for cytokine production, a method more suitable for field settings due to low costs and less labour and equipment intensive, others have measured cytokines by plasma levels 12, 16 or blood mononuclear cell mRNA 14 all these assays measure different aspects of cytokine production and should perhaps not be expected to provide comparable results.
Although our trial and another large trial that also measured both cytokine and clinical outcomes (related to obesity) 16 found agreement between lack of effects on both clinical and cytokine outcomes, it remains possible that other patient populations would benefit both clinically and in terms of cytokine production if given vitamin D. There has been notably heterogeneity to date among populations studied and cytokine assays in this field, which may be the main reasons for discrepant responses. 17,20 --23 Further large trials combining clinical and cytokine data in other populations are needed in order to determine where vitamin D is likely to be a useful intervention to improve immunity and responses to infections.
Although not a primary aim of our study and not based on the randomized controlled trial design, we have results that add to the current debate whether or not 25OHD, like many other measures of micronutrient status, is affected by acute phase responses.
5 --7 Plasma CRP was not associated with 25OHD but this could be because CRP levels were generally low; others have also shown that infants have low CRP responses to stimuli of acute phase responses. 24 Serious morbidity resulting in hospitalization during the preceding 6 months was not associated with plasma 25OHD and the only reported symptom in the past 3 days associated with plasma 25OHD was diarrhoea, which may have been a chance finding. It could be argued that the 6-month interval was too long and the 3 days too short to investigate this. Since there is no agreement as to whether there are changes in 25OHD during acute phase responses, there is certainly no agreement on the time course of such changes and these are likely influenced by the fact that sick patients may spend less time outdoors exposed to sunlight. 25 In summary, we observed that cytokine responses, like clinical morbidity symptoms, did not appear to be affected by 6 months of weekly vitamin D supplementation in deficient low birth weight term infants. 25OHD as a marker of vitamin D status was also not affected by infections. Further investigations of these issues are needed for validating the findings and investigating the effect of vitamin D supplementation on cytokine responses in other populations. 
